Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Adjuvant Nivolumab Plus Relatlimab Misses the Mark in Resected Stage III to IV Melanoma
June 3rd 2025, 7:33pm
Relatlimab plus nivolumab did not improve RFS over nivolumab alone in resected stage III to IV melanoma, per the final phase 3 RELATIVITY-098 results.
Darolutamide Plus ADT Confers HRQOL Benefits in Metastatic Hormone-Sensitive Prostate Cancer
June 3rd 2025, 6:10pm
A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.
SC Daratumumab Plus VRd Displays Durable Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma
June 3rd 2025, 5:42pm
Daratumumab plus VRd continued to demonstrate improvements in MRD negativity and PFS in newly diagnosed, transplant-ineligible multiple myeloma.
Ziftomenib Yields Complete Responses Regardless of Prior Therapy in NMP1-Mutant AML
June 3rd 2025, 5:05pm
Ziftomenib monotherapy elicited clinically meaningful, MRD-negative responses, including CRs, in heavily pretreated, relapsed/refractory NPM1-mutant AML.
Consolidation Benmelstobart ± Anlotinib Provides Substantial PFS Benefits in Stage III NSCLC
June 3rd 2025, 2:28pm
Benmelstobart with or without anlotinib boosted progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.
Neoadjuvant Nivolumab Plus Chemo Significantly Improves OS Vs Chemo in Resectable NSCLC
June 3rd 2025, 2:25pm
Neoadjuvant nivolumab plus chemo significantly improved OS vs chemo alone in resectable NSCLC, supporting practice-changing potential.
Niraparib/Abiraterone Is Effective for HRR+ Metastatic Castration-Sensitive Prostate Cancer
June 3rd 2025, 12:00pm
Niraparib plus abiraterone acetate and prednisone improved rPFS vs abiraterone acetate and prednisone and placebo in patients with mCSPC with alterations in HRR genes.
Dellphi-304 Data Reinforce Role of Tarlatamab as Second-Line SOC in Small Cell Lung Cancer
June 3rd 2025, 12:24am
Tarlatamab improved overall survival and progression-free survival in the second-line treatment of small cell lung cancer.
Neoadjuvant Osimertinib Yields MPRs With or Without Chemotherapy in Resectable EGFR-Mutated NSCLC
June 3rd 2025, 12:00am
Neoadjuvant osimertinib as monotherapy or plus chemotherapy was more effective vs chemotherapy alone in patients with resectable EGFR-mutated NSCLC.
Lifileucel Sustains Long-Term Responses and Survival in Advanced Melanoma
June 2nd 2025, 11:02pm
Second-line lifileucel generated durable responses and survival signals in patients with advanced melanoma, according to a 5-year analysis.
Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor Progression
June 2nd 2025, 10:33pm
Gino Kim In, MD, shares findings from a subgroup analysis of RP1 efficacy in injected and non-injected melanoma lesions after PD-1 inhibitor progression.
Dr Tolaney on the PFS Benefit With First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer
June 2nd 2025, 10:24pm
Sara M. Tolaney, MD, MPH, shares interim efficacy results from the DESTINY-Breast09 study of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.
COCOON DM Regimen Reduces Amivantamab/Lazertinib Effects on QOL in EGFR-Mutated NSCLC
June 2nd 2025, 9:35pm
COCOON DM reduced the severity and QOL influence of dermatologic AEs vs SOC DM in EGFR-mutant, advanced NSCLC treated with amivantamab plus lazertinib.
D-VRd Retains Its Role as a Potential Standard of Care for Transplant-Ineligible Multiple Myeloma
June 2nd 2025, 8:40pm
D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.
Dr Duska on the Role of Immunotherapy With Definitive Treatment in High-Risk, Locally Advanced Cervical Cancer
June 2nd 2025, 8:32pm
Linda R. Duska, MD, MPH, on incorporating immunotherapy into definitive therapy for high-risk, locally advanced cervical cancer.
Frontline Disitamab Vedotin Yields Responses in Gastric/GEJ Cancer With Various HER2 Expression Levels
June 2nd 2025, 8:25pm
The addition of disitamab vedotin to toripalimab and trastuzumab and/or CAPOX led to favorable response rates in HER2-expressing gastric/GEJ cancer.
Relacorilant Combo Improves PFS, Trends Toward Superior OS in Platinum-Resistant Ovarian Cancer
June 2nd 2025, 8:07pm
Relacorilant plus nab-paclitaxel showed meaningful PFS and OS gains, offering a potential new option for patients with platinum-resistant ovarian cancer.
Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer
June 2nd 2025, 7:39pm
Dostarlimab/chemotherapy plus maintenance niraparib showed clinically modest PFS improvements vs niraparib alone in newly diagnosed advanced ovarian cancer.
Dr Hamilton on Vepdegestrant vs Fulvestrant in ER+/HER2-Negative Advanced Breast Cancer
June 2nd 2025, 7:33pm
Sarah Cannon Research Institute
Erika Hamilton, MD, discusses data for vepdegestrant vs fulvestrant in ER-positive, HER2-negative advanced breast cancer.
EBC-129 Is Active and Safe in Heavily Pretreated mPDAC
June 2nd 2025, 7:25pm
EBC-129 monotherapy was active, generated responses, and had a manageable safety profile in heavily pretreated metastatic pancreatic ductal adenocarcinoma.